Interstitially implanted I125 for prostate cancer using transrectal ultrasound.
Prostate cancer is the third leading cause of death from cancer among men in the United States. Traditional treatments for prostate cancer are prostatectomy, external beam irradiation, and interstitial implantation of Iodine125 (I125) via laparotomy. These treatments are associated with significant morbidity and limitations. Based on experience with I125 interstitial implantation by transrectal ultrasound guidance for early-stage prostate cancer, it seems that this newer method of treatment has greater accuracy of placement and distribution of the isotope and has had few reported complications. The need for a surgical incision has been eliminated. Hospitalization time also has been decreased, creating the need for ambulatory and inpatient nurses to understand the importance of their respective roles in providing coordinated quality care for these patients. Nurses in these departments must have knowledge of the procedure, radiation safety, and common side effects related to the implant.
Greenburg
S
S
Northwest Tumor Institute, Seattle, WA.
Petersen
J
J
Hansen-Peters
I
I
Baylinson
W
W
D001918:Brachytherapy / Q000009:adverse effects / Q000451:nursing*; D006801:Humans; D007457:Iodine Radioisotopes / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D010347:Patient Care Planning; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging / Q000451:nursing / Q000532:radiotherapy*; D011879:Radiotherapy Dosage; D012007:Rectum; D014463:Ultrasonography
D007457:Iodine Radioisotopes